In the present study, proteomic analysis of serum EVs revealed a novel biomarker, Fibulin-3, that increases with liver fibrosis and can predict liver-related events in patients with MASLD. This evidence concerns the gene EFEMP1 and metabolic dysfunction-associated steatotic liver disease.